"The broader question is what other intellectual property is there in the Australian market that is similarly under-valued in the eyes of US investors. In my view Oncosil, etc, etc and etc are at the pointy end of the candidate list."
They've picked OSL first. Given there valuation of $0.41 and Wilson HTM at $0.38 (unrisked $2.20). This still looks very, very undervalued.
Even institutions will now have a better understanding of value in this space and its potential.
Numerous suitors looked at SRX. Expect attention to come to OSL, once their more comprehensive study results are out later in February. That said it was a good start with 100% Disease Control Rates at Week 8 and 90% at Week 16. Tumour reduction was also great at u[ to 72% 12 weeks post implant.
If they back these up in the next month with greater subject numbers - this is going much, much higher.
OSL Price at posting:
16.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)